

Allscripts®

Allscripts Healthcare Solutions Investor Presentation

September 2018



Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including the statements under “2018 Outlook”. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made (or any other specified date), and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts actual results to differ materially from those described in the forward-looking statements include, but are not limited to: the timing and ultimate completion of the expected sale of our interests in the Netsmart joint business entity; the expected proceeds and uses thereof from the expected sale of our interests in the Netsmart joint business entity; the expected financial contribution from businesses acquired by Allscripts, including the hospital and health systems business acquired from McKesson Corporation the “EIS Business”), the provider/patient solutions business acquired from NantHealth, Practice Fusion and HealthGrid; the successful integration of businesses acquired by Allscripts; the anticipated and unanticipated expenses and liabilities related to the businesses acquired by Allscripts; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; Allscripts failure to compete successfully; consolidation in Allscripts industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts or its customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts sales, services and support organizations; market acceptance of Allscripts products and services; the unpredictability of the sales and implementation cycles for Allscripts products and services; Allscripts ability to manage future growth; Allscripts ability to introduce new products and services; Allscripts ability to establish and maintain strategic relationships; risks related to the acquisition of new companies or technologies; the performance of Allscripts products; Allscripts ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts ability to hire, retain and motivate key personnel; performance by Allscripts content and service providers; liability for use of content; security breaches; price reductions; Allscripts ability to license and integrate third party technologies; Allscripts ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts business is contained in Allscripts filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in the most recent Allscripts Annual Report on Form 10-K and subsequent Form 10-Qs. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition or operating results over time.

Non-GAAP Financial Measures

This presentation includes references to non-GAAP revenue, gross profit, gross margin, and Adjusted EBITDA, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Each of these measures adjusts for certain items and are not considered financial measures under generally accepted accounting principles in the United States (“GAAP”).

- Non-GAAP revenue consists of GAAP revenue and adds back deferred revenue from the Netsmart transaction that is eliminated for GAAP purposes due to purchase accounting adjustments.
- Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related deferred revenue adjustments, acquisition-related amortization, stock-based compensation expense and transaction-related and other costs.
- Non-GAAP gross margin consists of non-GAAP gross profit as a percentage of GAAP revenue in the applicable period, as defined above.
- Adjusted EBITDA is a non-GAAP measure and consists of GAAP net income (loss) as reported and adjusts for: acquisition-related deferred revenue adjustments; depreciation and amortization; stock-based compensation expense; transaction-related and other costs; non-cash asset impairment charges; interest expense and other, net; equity in net earnings of unconsolidated investments; and tax provision (benefit).

Management also believes that non-GAAP measures provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein. Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP measures to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit, and gross margin are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained in the Appendix to this presentation. For the purpose of providing financial guidance, the company does not reconcile non-GAAP revenue, non-GAAP earnings, Adjusted net EBITDA or non-GAAP earnings per share guidance to the corresponding GAAP financial measures. Allscripts does not provide guidance for the various reconciling items since certain items that impact GAAP revenue and net income are either outside of its control and/or cannot be reasonably predicted. These are available on Allscripts investor relations website (<http://www.investor.Allscripts.com>).



Investment Considerations



Allscripts offers a **robust and diversified** solutions portfolio



Double digit non-GAAP earnings growth



Supported by a **high recurring revenue** model



Track record of **successful capital deployment**



Significant **operating leverage**



Secular shift to value-based care drives global investment in IT

We enable providers to optimize value at the point of care

A Global Leader in Healthcare Technology

Our Company



NASDAQ: MDRX
Public since 1999

Global HQ: Chicago, IL

LTM 6/30/18 Non-GAAP
Revenue: \$2.1B
79% recurring

Our Team



~9,400 team
associates globally

Veteran executive leadership

Clients, team members in 13
countries incl. Australia, Canada,
Israel & UK

A Complete and Diverse Portfolio

Precision Medicine & Consumer Solutions

Integrated, actionable genomic information delivered directly into clinical workflow.

Electronic Health Record

The power of Allscripts EHRs extends across the continuum, connecting healthcare communities.



Population Health Management

CareInMotion™ addresses every element of the population health equation.

Financial Management

Management and operational efficiency.

Coordinated care and healthy communities



75K+
Physician Practices
Including Practice Fusion



370 Unique
Data Sources



4B+
**Open API Data
Shares**



14M+ Referrals
Coordinated Community
and Post-acute



3,400
Hospitals



13M+
**Connected
Consumers**

We're recognized by the industry



- **2018 #1 Rehabilitation Hospitals and #1 Hospital Chains, IDNs and Networks for Integrated EHR, Interoperability, Population Health and Revenue Cycle Solutions**
- **2018 #1 Physician Practices 26-99 Providers**
- **2014-2017 #1 Inpatient EHR**
- **2017 #1 Population Health Management Solution**
- **2014-2017 Top Ambulatory EHR**



- **2018 Best in KLAS Anesthesia—iProcedures**
- **2017 Highest in usability in small practice ambulatory EHR | PM**
- **2016 Highest in usability in Population Health Management Report—Population Health UX**
- **2015–2016, 2013 Lab Best in KLAS**
- **2014, 2013, 2003-2010 ERP Best in KLAS**
- **7 straight years Paragon Best in KLAS Community HIS**



- **2017 Microsoft HIT Partner of the Year**
- **2015 Microsoft CXO Next Innovation Award**
- **2015 Microsoft Health User Group Innovation Award**



- **2018 Becker's Hospital Review Top Places to Work in Healthcare**



- **2017 USA Ambulatory Revenue Cycle Management Company of the Year**

Allscripts®

Growth Opportunity



Future Growth Streams



Organic
growth in
traditional
markets



Growth as
an industry
consolidator



Payer and
Life Sciences



Global
Markets

Our unique growth opportunities—unmatched by any HIT provider

Organic growth in traditional healthcare



Recurring Services

- Professional Services
- Hosting
- Managed Services
- Revenue Cycle Management Services

Value-based Care Tools

- Connects & aggregates community data to create harmonized view of patient
- Care coordination sets clinical interventions into action
- Financial performance management & decision support
- Precision Medicine
- Comprehensive solutions including risk analytics, content and service offerings
- Widely deployed consumer engagement platform with additional opportunities for cross-selling

Growth as an industry consolidator



Revenue based HIT Vendor Share

		2017	
No.	Vendor	Revenue (millions)	% of Top 10 Share
1	Cerner	\$5,142	38%
2	Epic*	\$2,700	20%
3	Allscripts**	\$2,200	16%
4	athenahealth	\$1,220	9%
5	NextGen	\$531	4%
6	eClinicalWorks	\$492	4%
7	MEDITECH	\$481	4%
8	Greenway	\$315	2%
9	CPSI	\$277	2%
10	MEDHOST	\$143	1%


Source: Company filings, <https://www.healthcare-informatics.com/hci100/2018-hci-100-list>

- * Approximate revenue, numbers are not publicly available
- ** Assumes mid-point of 2018 revenue guidance which reflects the impact of EIS and Practice Fusion acquisitions.

Payer and Life Sciences



PLS serves payors and life sciences organizations with solutions that enable strong connections to care providers individuals





The healthcare industry is going through transformation and restructuring, creating a 'New Normal' for our customers

Pharma

- Margins are significantly higher than others' in the value chain today – will be squeezed
- Market access is a challenge; a “science wins” strategy will always prevail, but distinctive differentiation is getting harder to prove
- They are **seeking solutions that help demonstrate value and improve commercialization initiatives**

Payors

- Market is already consolidated; payors have run out of room to use M&A to address rising healthcare costs
- Focused on improving experience to differentiate on more than price and avoid commodification
- They are **seeking solutions to help reduce costs and improve member experience**

Pharmacy / PBMs

- Ongoing financial pressures on brick and mortar has led to consolidation amongst retailer pharmacies but appears to have run its course
- PBMs are tightening control of drugs, using their market leverage to drive lower drug costs
- They are **seeking solutions to help manage specialty drug spend** and help them shift away from traditional unit cost model

Intermediaries (CROs, HIT, etc.)

- Cost of conducting research and demonstrating value continues to rise in part due to new regulations (i.e., 21st Century Cures Act)
- Winners are solving industry hassles primarily through tech solutions and by reducing cost
- They are **seeking solutions that give them access to healthcare data / insights** so that they can convert their businesses to be technology driven



We have developed a number of solutions for our customers though much of our portfolio has yet to reach maturity

Emerging



- Clinical research solutions

Growing



- Clinical workflow solutions
- Data and analytics solutions
- Health plan solutions

Mature



- Practice Fusion EHR

Connect PLS customers to PLS provider and patient network

EHR platform enabler



Positioning and Strategy

- Consolidating markets where larger players will make single decisions
- U.K., Australia, others lag in healthcare digital automation
- Outstanding reputation and presence in English speaking countries
- Multi-site – strategic “client partners”
- Leverage Allscripts integrated platform
- Complete solution: clinical/financial, value-based and population care

Allscripts Value Proposition

- Innovative solutions and open architecture
- Low risk implementations aligned w/ client requirements
- Subscription, SaaS model
- Capex/op-ex flexibility
- Ability to localize the solutions effectively
- Supports vision for a health economy
- Demonstrated outcomes



**Currently ~5%
of total corporate
revenue**



**Plan to grow
multi-fold**


Allscripts®

Financial Model




1st Half Sales Trends


Bookings



Recurring Revenue




Non-Recurring Revenue




Dollars in millions. See reconciliation of non-GAAP metrics in the appendix of this presentation.

Strong Annual Sales Trends


Bookings



Recurring Revenue




Non-Recurring Revenue




Dollars in millions. See reconciliation of non-GAAP metrics in the appendix of this presentation.

Strong Margin Profile – 1st Half

Gross Profit & Margin




Adjusted EBITDA & Margin




Dollars in millions. See reconciliation of non-GAAP metrics in the appendix of this presentation.

Expanding Margins

Gross Profit & Margin





Adjusted EBITDA & Margin



Dollars in millions. See reconciliation of non-GAAP metrics in the appendix of this presentation.

Recent Quarterly Results: 2Q 2018

Bookings	\$278M		
Backlog	\$4.768B		16%
Non-GAAP Revenue	\$536M		25%



See reconciliation of non-GAAP metrics in the appendix of this presentation.

Strong Cash Generation Enabling Balanced Approach to Value Creation

Invest to accelerate growth

- Continue to innovate across our growth pillars
- Gross R&D spend

M&A

- Maintain balance sheet flexibility allowing for opportunistic M&A
 - Enterprise Information Solutions (new core segment – small hospitals)
 - Practice Fusion (expand addressable market)
 - Core Medical Solutions (global – new geography)
 - Careport (value-based care innovation)
 - HealthGrid (expand patient engagement solution)

Share repurchase

- \$250M remaining under current authorization through 2020
- In 2018, repurchases = \$102M through 6/30/18
- In 2017, repurchases = \$12M
- In 2016, repurchases = \$121M

Track Record of Successful Capital Deployment

Netsmart

- Signed letter of intent to sell our interest in the Netsmart joint venture
- Contributed 100% of Homecare business, plus approximately \$70 million in cash to the joint venture in April 2016
- Anticipate using proceeds to pay down debt and opportunistically repurchase shares

Enterprise Information Solutions

- Purchased for \$185M
- Strengthens Allscripts community hospital offering (Paragon)
- Doubles Allscripts base of core EHR and RCMS hospitals
- Adds incremental, high-margin ancillary solutions
- Opens incremental cross-selling opportunities
- Sold OneContent and recognized gain of \$178M

Practice Fusion

- Purchased for \$100M
- Expands Allscripts market leadership in Payer & Life Sciences
- Allscripts is largest EHR provider to physicians *
- Cloud based technology
- Shift to paid subscription model has exceeded expectations

* Source: SK&A market share analysis March, 2017

2018 Outlook

Non-GAAP Revenue

- \$2.15 billion to \$2.25 billion

Adjusted EBITDA

- \$420 million to \$460 million, consisting of:
- Allscripts, excluding Netsmart, Adjusted EBITDA between \$310-\$340 million
 - Netsmart Adjusted EBITDA between \$110-\$120 million

Non-GAAP EPS

- \$0.72 to \$0.82
- Growth of 16%-32%

Note: Based on our affirmation in our August 2, 2018 disclosure.

Investment Considerations



Allscripts offers a **robust and diversified** solutions portfolio



Double digit non-GAAP earnings growth



Supported by a **high recurring revenue** model



Track record of **successful capital deployment**



Significant **operating leverage**



Secular shift to value-based care drives global investment in IT

We enable providers to optimize value at the point of care



Appendix: Non-GAAP Reconciliations

Reconciliations: Rec/Non-Rec and SW/Services

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information

(In millions)

(unaudited)

	2015	2016	2017
	Total	Total	Total
Non-GAAP Revenue			
Software Delivery, Support & Maintenance			
Recurring revenue	781.0	864.7	1,010.6
Non-recurring revenue	137.4	168.2	191.3
Total Software Delivery, Support & Maintenance	918.4	1,032.9	1,201.9
Client Services			
Recurring revenue	271.8	352.5	420.9
Non-recurring revenue	196.2	190.3	218.0
Total Client Services	468.0	542.8	638.9
Total non-GAAP revenue	1,386.4	1,575.7	1,840.8
Acquisition-related deferred revenue adjustments	0.0	25.8	34.5
Total revenue, as reported	1,386.4	1,549.9	1,806.3

Reconciliations: 1H Rec/Non-Rec and SW/Services

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information

(In millions)

(unaudited)

	1H 2015	1H 2016	1H 2017	1H 2018
	Total	Total	Total	Total
Non-GAAP Revenue				
Software Delivery, Support & Maintenance*				
Recurring revenue	392.9	409.8	452.4	593.3
Non-recurring revenue	67.2	77.3	92.2	80.3
Total Software Delivery, Support & Maintenance	460.1	487.1	544.6	673.6
Client Services*				
Recurring revenue	127.9	162.2	205.3	256.0
Non-recurring revenue	98.3	92.9	92.9	124.8
Total Client Services	226.2	255.1	298.2	380.8
Total non-GAAP revenue	686.3	742.2	842.8	1,054.4
Acquisition-related deferred revenue adjustments	0.0	10.1	3.2	14.9
Total revenue, as reported	686.3	732.1	839.6	1,039.5

Reconciliations: Adjusted EBITDA & Margins ('15-16)

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - Adjusted EBITDA

(In millions, except percentages)

(Unaudited)

	Year Ended December 31,	
	2016	2015
Total revenue, as reported	\$1,549.9	\$1,386.4
Acquisition-related deferred revenue adjustments	25.8	-
Total non-GAAP revenue	\$1,575.7	\$1,386.4
Net income (loss), as reported	3.0	(\$2.0)
Acquisition-related deferred revenue adjustments	25.8	-
Depreciation and amortization	172.4	161.0
Stock-based compensation expense	44.2	36.6
Non-recurring expenses and transaction-related costs	13.4	23.4
Non-cash asset impairment charges	4.7	1.5
Interest expense and other, net (a)	50.5	17.4
Equity in net earnings of unconsolidated investments	7.5	2.1
Tax (benefit)/provision	(17.8)	2.6
Adjusted EBITDA	\$303.7	\$242.6
<i>Adjusted EBITDA margin (b)</i>	19%	17%

(a) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.

(b) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by non-GAAP revenue.

Reconciliations: Adjusted EBITDA & Margins ('17)

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information - Adjusted EBITDA

(In millions, except percentages)

(Unaudited)

	<u>Year Ended</u> <u>December 31,</u> <u>2017</u>
Total revenue, as reported	\$1,806.3
Acquisition-related deferred revenue adjustments	34.5
Total non-GAAP revenue	\$1,840.8
Net income (loss) from continuing operations, as reported	(158.9)
Acquisition-related deferred revenue adjustments	34.5
Depreciation and amortization	218.5
Stock-based compensation expense	41.7
Transaction-related and other costs (a)	55.0
Non-cash asset impairment charges	0.0
Interest expense and other, net (b)	69.0
Impairment of and losses on long-term investments	165.3
Equity in net loss of unconsolidated investments	(0.8)
Tax (benefit)/provision	(50.7)
Adjusted EBITDA	\$373.6
<i>Adjusted EBITDA margin (c)</i>	<i>20%</i>

(a) Transaction-related and other costs has been adjusted from the amounts presented in the reconciliation of GAAP and non-GAAP income from operations, as shown in Table 4, in order to remove the accelerated amortization of assets to be disposed from transaction-related and other costs since such amortization is

(b) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such

(c) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by non-GAAP revenue.

Reconciliations: Adjusted EBITDA & Margins (1H '15-16)

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - Adjusted EBITDA

(In millions, except percentages)
(Unaudited)

	Six Months Ended June 30,	
	2016	2015
Total revenue, as reported	\$732.1	\$686.3
Acquisition-related deferred revenue adjustments	10.1	0.0
Total non-GAAP revenue	\$742.2	\$686.3
Net (loss) income, as reported	\$0.0	(\$13.3)
Acquisition-related deferred revenue adjustments	10.1	0.0
Depreciation and amortization	76.6	83.5
Stock-based compensation expense	21.1	19.5
Non-recurring expenses and transaction-related costs	4.6	13.5
Non-cash asset impairment charges	4.7	0.3
Interest expense and other, net (a)	15.2	7.7
Equity in net earnings of unconsolidated investments	7.5	0.0
Tax (benefit)/provision	0.1	0.5
Adjusted EBITDA	139.9	111.7
<i>Adjusted EBITDA margin (b)</i>	<i>19%</i>	<i>16%</i>
Less: Adjusted EBITDA attributable to non-controlling interest	8.8	0.0
Adjusted net EBITDA, net of non-controlling interest	\$131.1	\$111.7
<i>Adjusted net EBITDA margin, net of non-controlling interest (c)</i>	<i>18%</i>	<i>16%</i>

(a) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.

(b) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by total revenue

(c) Adjusted net EBITDA margin, net of non-controlling interest is calculated by dividing adjusted net EBITDA, net of non-controlling interest by total revenue.

Reconciliations: Adjusted EBITDA & Margins (1H '17-18)

Allscripts Healthcare Solutions, Inc.

Non-GAAP Financial Information - Adjusted EBITDA

(In millions, except percentages)

(Unaudited)

	<u>Six Months Ended June 30,</u>	
	<u>2018</u>	<u>2017</u>
Total revenue, as reported	\$1,039.5	\$839.6
Acquisition-related deferred revenue adjustments	14.9	3.2
Total non-GAAP revenue	<u>\$1,054.4</u>	<u>\$842.8</u>
Net income (loss) from continuing operations, as reported	42.0	(\$151.6)
Acquisition-related deferred revenue adjustments	14.9	3.2
Depreciation and amortization	132.2	101.3
Stock-based compensation expense	22.3	20.0
Transaction-related and other costs (a)	66.5	21.4
Interest expense and other, net (b)	42.2	31.5
Asset impairment charges	30.1	-
Impairment of and losses on long-term investments	15.5	144.6
Gain on sale of business, net	(172.3)	0.0
Equity in net income of unconsolidated investments	(0.8)	(0.3)
Tax (benefit)/provision	0.8	(0.8)
Adjusted EBITDA	<u>\$193.4</u>	<u>\$169.3</u>
<i>Adjusted EBITDA margin (c)</i>	<i>18%</i>	<i>20%</i>

(a) Transaction-related and other costs has been adjusted from the amounts presented in the reconciliation of GAAP and non-GAAP income from operations, as shown in Table 4, in order to remove the accelerated amortization of assets to be disposed from transaction-related and other costs since such amortization is also included in depreciation and amortization.

(b) Interest expense and other, net has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.

(c) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by non-GAAP revenue.

Reconciliations: Non-GAAP Gross Profit and Margin

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information
(In millions)
(unaudited)

	2015	2016	2017
	Total	Total	Total
Software Delivery, Support & Maintenance			
Revenue, as reported	918.4	1,012.4	1,174.7
Acquisition-related deferred revenue and other adjustments	0.0	20.5	27.2
Total non-GAAP revenue	918.4	1,032.9	1,201.9

Gross profit, as reported	544.4	599.5	692.2
Acquisition-related deferred revenue and other adjustments	0.0	20.5	27.2
Acquisition-related amortization	35.1	45.3	57.6
Stock-based compensation expense	4.2	4.3	2.9
Transaction-related and other special costs	0.0	0.0	0.0
Non-GAAP gross profit	583.7	669.6	779.9

Client Services

Revenue, as reported	468.0	537.5	631.6
Acquisition-related deferred revenue and other adjustments	0.0	5.3	7.3
Total non-GAAP revenue	468.0	542.8	638.9

Gross profit, as reported	36.2	71.5	89.9
Acquisition-related deferred revenue and other adjustments	0.0	5.3	7.3
Stock-based compensation expense	4.5	4.5	4.6
Transaction-related and other special costs	0.0	0.6	0.3
Non-GAAP gross profit	40.7	81.9	102.1

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information
(In millions)
(unaudited)

	2015	2016	2017
	Total	Total	Total
Non-GAAP Revenue	45.0%	47.7%	47.9%
Total non-GAAP gross margin			

Reconciliations: 1H Non-GAAP Gross Profit and Margin

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information
(In millions)
(unaudited)

	1H '15	1H '16	1H '17	1H '18
	Total	Total	Total	Total
Software Delivery, Support & Maintenance				
Revenue, as reported*	460.1	479.0	543.3	666.2
Acquisition-related deferred revenue and other adjustments	0.0	8.1	1.3	7.4
Total non-GAAP revenue	460.1	487.1	544.6	673.6

Gross profit, as reported	265.8	286.7	316.8	380.9
Acquisition-related deferred revenue and other adjustments	0.0	8.1	1.3	7.3
Acquisition-related amortization	18.3	19.0	28.2	31.6
Stock-based compensation expense	2.3	2.3	2.1	1.1
Transaction-related and other special costs	0.0	0.0	0.0	3.7
Non-GAAP gross profit	286.4	316.1	348.4	424.6

Client Services

Revenue, as reported*	226.2	253.1	296.3	373.3
Acquisition-related deferred revenue and other adjustments	0.0	2.0	1.9	7.5
Total non-GAAP revenue	226.2	255.1	298.2	380.8

Gross profit, as reported	7.6	31.8	49.3	52.7
Acquisition-related deferred revenue and other adjustments	0.0	2.0	1.9	7.5
Stock-based compensation expense	2.7	2.6	2.6	2.5
Transaction-related and other special costs	0.0	0.0	0.2	9.8
Non-GAAP gross profit	10.3	36.5	54.0	72.5

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information
(In millions)
(unaudited)

Non-GAAP Gross Margin
Total non-GAAP gross margin

1H '15	1H '16	1H '17	1H '18
Total	Total	Total	Total
43.2%	47.5%	47.7%	47.2%